Friday Celldex Therapeutics Inc (CLDX) $CLDX opened at 14.76 hitting the high price of 15.00 and a day low of 14.13 with a total volume of 1,541,300. CLDX had a previous close of 14.64 and has been seeing an average volume of 2,637,265.
Overall Average: 56% Sell
Recent stock forum discussions about CLDX http://investorshangout.com/search?q=CLDX&...mp;yt0=Go!
Celldex to Present at Two Upcoming Investor Conferences
GlobeNewswire - Fri May 02, 10:45AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 39 Annual Healthcare Conference on Wednesday, May 7, 2014 at 11:20 a.m. ET at the InterContinental Hotel in Boston and at the Bank of America Merrill Lynch 2014 Healthcare Conference on Wednesday, May 14, 2014 at 4:20 p.m. PT at the Encore at the Wynn in Las Vegas. (full story)
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa (full story)
Celldex Reports First Quarter 2014 Results
GlobeNewswire - Thu May 01, 7:13AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2014. (full story)
Top Gainers at a Glance -- Research on Ameriprise Financial, Endeavour Silver, Celldex Therapeutics, and Buffalo Wild Wings
PR Newswire - Thu May 01, 3:20AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session at 16,535.37, up 0.53% and the S&P 500 finishing 0.48% higher at 1,878.33. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Ameriprise Financial Inc. (NYSE: AMP), Endeavour Silver Corp. (NYSE: EXK), Celldex Therapeutics Inc. (NASDAQ: CLDX) and Buffalo Wild Wings Inc. (NASDAQ: BWLD). Free technical research on AMP, EXK, CLDX and BWLD can be downloaded upon signing up at: (full story)
Downtrend Call Working As Celldex Therapeutics Stock Falls 41.7% (CLDX)
Comtex SmarTrend(R) - Wed Apr 30, 9:38AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 41.68% as of today's recent price of $14.47. (full story)
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver
PR Newswire - Tue Apr 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMCSA, GILD, CIEN, ADBE, and CLDX. (full story)
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease (full story)
Celldex Therapeutics Has Returned 36.7% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Wed Apr 23, 9:12AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 1 month, Celldex Therapeutics has returned 36.68% as of today's recent price of $15.71. (full story)
First Week of CLDX June 21st Options Trading
DividendChannel.com - Tue Apr 22, 11:55AM CDT
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the June 21st expiration. (full story)
Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine
GlobeNewswire - Wed Apr 16, 1:49PM CDT
--First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity-- (full story)
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global (full story)
44.7% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Apr 15, 4:44PM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 1 month, Celldex Therapeutics has returned 44.66% as of today's recent price of $13.73. (full story)
After Yesterday's Decline of 2.14%, Celldex Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 5:52PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $13.41 to a high of $14.67. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $13.93 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free (full story)
Celldex Therapeutics Rises 9.18% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 5:10PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $15.66 to a high of $17.07. Yesterday, the shares gained 9.2%, which took the trading range above the 3-day high of $16.75 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014. (full story)
Shares of CLDX Down 36.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 11:03AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 4 weeks, Celldex Therapeutics has returned 35.99% as of today's recent price of $15.88. (full story)
5 Stocks Forging the Future of Breast Cancer Care
George Budwell, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Breast cancer is the second leading cause of cancer deaths among women, falling second only to lung cancer. Fortunately, the mortality rate has steadily declined since 1989, partly because of earlier detection through regular screenings and improved... (full story)
Celldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data presented at AACR 2014
GlobeNewswire - Mon Apr 07, 3:00PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate (ADC) that targets the protein TIM-1 (T cell immunoglobulin and mucin domain). TIM-1 expression is upregulated in several cancers, including renal cell and ovarian carcinomas. It is associated with kidney injury and the shedding of its ectodomain is a predictive biomarker for tumor progression. TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The data were presented in a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2014. (full story)
3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ... (full story)
Overall Average: 56% Sell
Recent stock forum discussions about CLDX http://investorshangout.com/search?q=CLDX&...mp;yt0=Go!
Celldex to Present at Two Upcoming Investor Conferences
GlobeNewswire - Fri May 02, 10:45AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 39 Annual Healthcare Conference on Wednesday, May 7, 2014 at 11:20 a.m. ET at the InterContinental Hotel in Boston and at the Bank of America Merrill Lynch 2014 Healthcare Conference on Wednesday, May 14, 2014 at 4:20 p.m. PT at the Encore at the Wynn in Las Vegas. (full story)
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa (full story)
Celldex Reports First Quarter 2014 Results
GlobeNewswire - Thu May 01, 7:13AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2014. (full story)
Top Gainers at a Glance -- Research on Ameriprise Financial, Endeavour Silver, Celldex Therapeutics, and Buffalo Wild Wings
PR Newswire - Thu May 01, 3:20AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session at 16,535.37, up 0.53% and the S&P 500 finishing 0.48% higher at 1,878.33. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Ameriprise Financial Inc. (NYSE: AMP), Endeavour Silver Corp. (NYSE: EXK), Celldex Therapeutics Inc. (NASDAQ: CLDX) and Buffalo Wild Wings Inc. (NASDAQ: BWLD). Free technical research on AMP, EXK, CLDX and BWLD can be downloaded upon signing up at: (full story)
Downtrend Call Working As Celldex Therapeutics Stock Falls 41.7% (CLDX)
Comtex SmarTrend(R) - Wed Apr 30, 9:38AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 2 months, Celldex Therapeutics has returned 41.68% as of today's recent price of $14.47. (full story)
Critical Alerts For Comcast, Gilead Sciences, Ciena, Adobe Systems, and Celldex Therapeutics Released By InvestorsObserver
PR Newswire - Tue Apr 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMCSA, GILD, CIEN, ADBE, and CLDX. (full story)
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease (full story)
Celldex Therapeutics Has Returned 36.7% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Wed Apr 23, 9:12AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 1 month, Celldex Therapeutics has returned 36.68% as of today's recent price of $15.71. (full story)
First Week of CLDX June 21st Options Trading
DividendChannel.com - Tue Apr 22, 11:55AM CDT
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the June 21st expiration. (full story)
Celldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine
GlobeNewswire - Wed Apr 16, 1:49PM CDT
--First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity-- (full story)
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global (full story)
44.7% Return Seen to Date on SmarTrend Celldex Therapeutics Call (CLDX)
Comtex SmarTrend(R) - Tue Apr 15, 4:44PM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 1 month, Celldex Therapeutics has returned 44.66% as of today's recent price of $13.73. (full story)
After Yesterday's Decline of 2.14%, Celldex Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 5:52PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $13.41 to a high of $14.67. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $13.93 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free (full story)
Celldex Therapeutics Rises 9.18% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 5:10PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $15.66 to a high of $17.07. Yesterday, the shares gained 9.2%, which took the trading range above the 3-day high of $16.75 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014. (full story)
Shares of CLDX Down 36.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 11:03AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on March 10th, 2014 at $24.81. In approximately 4 weeks, Celldex Therapeutics has returned 35.99% as of today's recent price of $15.88. (full story)
5 Stocks Forging the Future of Breast Cancer Care
George Budwell, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Breast cancer is the second leading cause of cancer deaths among women, falling second only to lung cancer. Fortunately, the mortality rate has steadily declined since 1989, partly because of earlier detection through regular screenings and improved... (full story)
Celldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data presented at AACR 2014
GlobeNewswire - Mon Apr 07, 3:00PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate (ADC) that targets the protein TIM-1 (T cell immunoglobulin and mucin domain). TIM-1 expression is upregulated in several cancers, including renal cell and ovarian carcinomas. It is associated with kidney injury and the shedding of its ectodomain is a predictive biomarker for tumor progression. TIM-1 has very restricted expression in healthy tissues, making it a promising target for antibody mediated therapy. The data were presented in a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2014. (full story)
3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ... (full story)
